Research programme: biodefence vaccines - AlphaVax

Drug Profile

Research programme: biodefence vaccines - AlphaVax

Alternative Names: Biodefense vaccines - AlphaVax; Botulinum toxin vaccine - AlphaVax; Ebola virus vaccine - AlphaVax; Equine encephalomyelitis virus vaccine - AlphaVax; Marburg virus vaccine - AlphaVax; Smallpox virus vaccine - AlphaVax; Venezuelan/Eastern/Western Equine Encephalitis virus vaccine - AlphaVax

Latest Information Update: 04 Sep 2007

Price : $50

At a glance

  • Originator AlphaVax
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Botulism; Encephalitis virus infections; Marburg virus disease; Smallpox

Most Recent Events

  • 04 Sep 2007 Preclinical development is ongoing
  • 23 Oct 2005 Preclinical trials in Smallpox in USA (unspecified route)
  • 03 Dec 2003 Preclinical trials in Marburg virus disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top